Signos Secures $20M to Expand CGM Use Beyond Diabetes Into Weight Loss

Signos raised $20 million to expand its glucose monitoring platform for weight loss, which pairs Dexcom’s over-the-counter CGM with an app that translates glucose data into personalized diet and lifestyle recommendations. The post Signos Secures $20M to Expand CGM Use Beyond Diabetes Into Weight Loss appeared first on MedCity News.